Literature DB >> 15554392

Expression of MUC1 recognized by a monoclonal antibody MY.1E12 is a useful biomarker for tumor aggressiveness of carcinoma of the gallbladder.

Toru Kawamoto1, Junichi Shoda, Naoki Miyahara, Hideo Suzuki, Masato Furukawa, Takeshi Todoroki, Naomi Tanaka, Tatsuro Irimura.   

Abstract

The overall outcome of gallbladder carcinoma has not been favorable because of frequent recurrence at distant sites after surgery. A high-level expression of MUC1 recognized by a monoclonal antibody (mAb), MY.1E12, is correlated with poor survival in several types of carcinomas. There is a need to find new prognostic parameters that can give further insights into tumor aggressiveness of the disease. Immunohistochemistry was performed to determine the expression level of mAb MY.1E12-reactive-MUC1 (MY.1E12-MUC1) in 79 cases of gallbladder carcinoma of different depths of invasion and to determine the correlation of the expression level with clinicopathological findings. The cellular distribution of MY.1E12-MUC1 was heterogeneous among carcinomas of different depths of invasion. Immunohistochemical localization was classified into apical, cytoplasmic and stromal types based on the predominant cellular distribution. In 35 cases of pT2 carcinoma in which curative resections had been performed, the localization was apical type in 54%, cytoplasmic type in 66%, and stromal type in 56% of the cases at the deepest invading sites in the subserosal layer. Postsurgical recurrences at distant sites were seen in 11 of 18 cases of pT2 carcinoma (61%) that had more than or equal to 10% of the cancerous epithelia showing stromal localization of MY.1E12-MUC1 at the deepest invading sites (stromal group) and in 3 of 17 cases (18%) that had less than 10% of the cancerous epithelia showing stromal localization (nonstromal group). The postsurgical 5-year survival rate was significantly poorer in the former (54%) than in the latter (79%; P = 0.049). In 38 cases of pT3 and pT4 carcinomas, the frequency of synchronous distant organ metastasis at the time of diagnosis was significantly higher in cases in the stromal group (61%) than in cases in the nonstromal group (20%). Moreover, in 73 cases of pT2, pT3 and pT4 carcinomas, the expression rate of abnormal localization of E-cadherin was significantly higher in the stromal group (63%) than in the nonstromal group (30%). The MUC1 mRNA levels revealed by in situ hybridization would not be a determinant important for the stromal localization. The stromal localization of MY.1E12-MUC1 may be a phenotype serving as a unique biological feature associated with the tumor aggressiveness of gallbladder carcinoma, such as the tendency to form distant organ metastasis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15554392     DOI: 10.1023/b:clin.0000046177.70405.cb

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  44 in total

1.  Expression of MUC1 mucins in the subserosal layer correlates with postsurgical prognosis of pathological tumor stage 2 carcinoma of the gallbladder.

Authors:  T Kawamoto; J Shoda; T Irimura; N Miyahara; M Furukawa; T Ueda; T Asano; M Kano; N Koike; K Fukao; N Tanaka; T Todoroki
Journal:  Clin Cancer Res       Date:  2001-05       Impact factor: 12.531

2.  Primary carcinoma of the gallbladder: TNM staging and prognosis.

Authors:  K White; W G Kraybill; M J Lopez
Journal:  J Surg Oncol       Date:  1988-12       Impact factor: 3.454

3.  Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma.

Authors:  M Higashi; S Yonezawa; J J Ho; S Tanaka; T Irimura; Y S Kim; E Sato
Journal:  Hepatology       Date:  1999-12       Impact factor: 17.425

Review 4.  Cancer metastasis. Organ colonization and the cell-surface properties of malignant cells.

Authors:  G L Nicolson
Journal:  Biochim Biophys Acta       Date:  1982-12-21

5.  Suppression of cellular aggregation by high levels of episialin.

Authors:  M J Ligtenberg; F Buijs; H L Vos; J Hilkens
Journal:  Cancer Res       Date:  1992-04-15       Impact factor: 12.701

6.  Abnormal expression of E-cadherin and beta-catenin may be a molecular marker of submucosal invasion and lymph node metastasis in early gastric cancer.

Authors:  M Tanaka; Y Kitajima; G Edakuni; S Sato; K Miyazaki
Journal:  Br J Surg       Date:  2002-02       Impact factor: 6.939

7.  Expression of apomucins in the intrahepatic biliary tree in hepatolithiasis differs from that in normal liver and extrahepatic biliary obstruction.

Authors:  M Sasaki; Y Nakanuma; Y S Kim
Journal:  Hepatology       Date:  1998-01       Impact factor: 17.425

8.  The clinical significance of the histologic subclassification of colorectal carcinoma.

Authors:  C R Teixeira; S Tanaka; K Haruma; M Yoshihara; K Sumii; G Kajiyama; F Shimamoto
Journal:  Oncology       Date:  1993 Nov-Dec       Impact factor: 2.935

9.  Sialyl-dimeric Lewis-X antigen expressed on mucin-like glycoproteins in colorectal cancer metastases.

Authors:  Y Matsushita; K R Cleary; D M Ota; S D Hoff; T Irimura
Journal:  Lab Invest       Date:  1990-12       Impact factor: 5.662

10.  MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma.

Authors:  S Nakamori; D M Ota; K R Cleary; K Shirotani; T Irimura
Journal:  Gastroenterology       Date:  1994-02       Impact factor: 22.682

View more
  6 in total

1.  MUC1 expression in pulmonary metastatic tumors: a comparison of primary lung cancer.

Authors:  Kyoichi Kaira; Takehiro Okumura; Kazuo Nakagawa; Yasuhisa Ohde; Toshiaki Takahashi; Haruyasu Murakami; Tateaki Naito; Masahiro Endo; Haruhiko Kondo; Takashi Nakajima; Nobuyuki Yamamoto
Journal:  Pathol Oncol Res       Date:  2011-10-02       Impact factor: 3.201

2.  MUC1 expression in thymic epithelial tumors: MUC1 may be useful marker as differential diagnosis between type B3 thymoma and thymic carcinoma.

Authors:  Kyoichi Kaira; Haruyasu Murakami; Masakuni Serizawa; Yasuhiro Koh; Masato Abe; Yasuhisa Ohde; Toshiaki Takahashi; Haruhiko Kondo; Takashi Nakajima; Nobuyuki Yamamoto
Journal:  Virchows Arch       Date:  2011-01-21       Impact factor: 4.064

3.  Expression of MUC1 recognized by monoclonal antibody MY.1E12 is a useful biomarker for tumor aggressiveness of advanced colon carcinoma.

Authors:  Hideo Suzuki; Junichi Shoda; Toru Kawamoto; Eiji Shinozaki; Naoki Miyahara; Souichi Hotta; Yasushi Iizuka; Akira Nakahara; Naomi Tanaka; Akinori Yanaka; Tatsuro Irimura
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

4.  Expression of N-acetylglucosaminyltransferase V in the subserosal layer correlates with postsurgical survival of pathological tumor stage 2 carcinoma of the gallbladder.

Authors:  Kenichiro Onuki; Hiroaki Sugiyama; Kazunori Ishige; Toru Kawamoto; Takehiro Ota; Shunichi Ariizumi; Masayuki Yamato; Shinichi Kadota; Kaoru Takeuchi; Akiko Ishikawa; Masafumi Onodera; Kojiro Onizawa; Masakazu Yamamoto; Eiji Miyoshi; Junichi Shoda
Journal:  J Gastroenterol       Date:  2013-04-17       Impact factor: 7.527

Review 5.  Epithelial-to-mesenchymal transition in gallbladder cancer: from clinical evidence to cellular regulatory networks.

Authors:  Sunwang Xu; Ming Zhan; Jian Wang
Journal:  Cell Death Discov       Date:  2017-11-27

6.  Expression of MUC1 and MUC4 in gallbladder adenocarcinoma.

Authors:  Su-Mi Kim; Sun-Ju Oh; Bang Hur
Journal:  Korean J Pathol       Date:  2012-10-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.